Interleukin-7

Summary

Interleukin-7 (IL-7) is a pleiotropic cytokine essential for T-cell development, survival, and homeostatic proliferation. Recombinant forms (e.g., CYT107/rhIL-7) are under clinical investigation for immune reconstitution in settings such as HIV/AIDS, sepsis-induced lymphopenia, cancer immunotherapy, and post-hematopoietic stem cell transplantation. No form is currently approved by major regulatory agencies for therapeutic use.

Mechanism of Action

Binds to the IL-7 receptor (IL-7Rα/CD127 paired with γc chain/CD132), activating JAK1/JAK3 and downstream STAT5 signaling pathways, promoting survival, proliferation, and differentiation of T lymphocytes and B lymphocyte precursors; critical for T-cell homeostasis and lymphocyte reconstitution.

Routes of Administration

Goals & Uses

• HIV-associated immune deficiencyInfectious Disease / ImmunologyModerate
• Sepsis-induced lymphopenia reversalCritical Care / ImmunologyModerate
• Graft-versus-host disease mitigation post-HSCTTransplant ImmunologyLow
• Cancer immunotherapy augmentationOncologyLow
• Vaccine immune response enhancementVaccinologyLow
• T-cell immune reconstitutionImmunologyModerate

Contraindications

• Hypersensitivity to IL-7 or excipientsAllergy / ImmunologyHigh
• Active graft-versus-host diseaseTransplant ImmunologyHigh
• Uncontrolled systemic infectionInfectious DiseaseModerate
• Hematologic malignancy with T-cell lineage involvementOncologyHigh
• Active autoimmune diseaseAutoimmunityHigh

Adverse Effects

• Skin rash / eosinophiliaDermatologic / HematologicUncommon
• Injection site reactionsLocalCommon
• ThrombocytopeniaHematologicUncommonLow platelet count
• Autoimmune manifestationsImmunologicRare
• Transient lymphadenopathyLymphaticCommon
• Flu-like symptoms / feverSystemicCommon

Drug Interactions

• Checkpoint inhibitors (e.g., pembrolizumab, nivolumab)Moderate
• JAK inhibitors (e.g., ruxolitinib, tofacitinib)High
• Immunosuppressants (e.g., tacrolimus, cyclosporine)Moderate
• CorticosteroidsModerate

Population Constraints

• Patients with T-cell malignanciesOncologyAbsolute
• Pediatric patientsAgeRelative
• Patients with pre-existing autoimmune diseaseAutoimmuneRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Elderly patients (>65 years)AgeRelative

Regulatory Status

• European UnionInvestigationalInvestigated under EMA oversight in multiple clinical trials; orphan designation granted for some forms in specific indications. No approved product as of 2024.
• United StatesInvestigationalMultiple IND-stage trials ongoing. CYT107 and NT-I7 (efineptakin alfa) have been studied; NT-I7 received Fast Track designation for certain indications. No FDA-approved indication as of 2024.
• United KingdomInvestigationalNo MHRA-approved IL-7 therapeutic product; clinical trial access only as of 2024.

No approved therapeutic IL-7 product exists in the US, EU, or UK as of 2024. Multiple recombinant forms are in Phase I/II clinical trials. CYT107 (glycosylated rhIL-7) has received orphan drug designation in some jurisdictions. Investigational use only.

Evidence & Sources

No sources recorded yet.